Table 3.
Patient and disease characteristics by metabolomic risk (eCRC cohort).
| Covariate | Whole Sample (N = 94) |
High (N = 40) |
Low (N = 54) |
p-Value |
|---|---|---|---|---|
| Age at study entry (years) | 78 (70–89) | 76 (70;85) | 78 (71;89) | 0.062 |
| Tumor localization (n,%) | 0.025 | |||
| • Left/Rectum | 57 (61) | 19 (48) | 38 (70) | |
| • Right | 37 (39) | 21 (52) | 16 (30) | |
| Tumor size (n,%) | 0.273 | |||
| • T1 | 1 (1) | 0 (0) | 1 (1) | |
| • T2 | 6 (6) | 3 (8) | 3 (6) | |
| • T3 | 72 (77) | 29 (72) | 43 (80) | |
| • T4 | 7 (7) | 2 (5) | 5 (9) | |
| • NA * | 8 (9) | 6 (15) | 2 (4) | |
| Nodal involvement (n,%) | 0.017 | |||
| • N0 | 41 (44) | 11(28) | 30 (56) | |
| • N1 | 28 (30) | 16 (40) | 12 (22) | |
| • N2 | 17 (18) | 7 (18) | 10 (19) | |
| • NA * | 8 (9) | 6 (15) | 2 (4) | |
| Histologic grade (n,%) | 0.495 | |||
| • Grade 1 | 6 (7) | 1 (3) | 5 (10) | |
| • Grade 2 | 67 (74) | 30 (79) | 37 (71) | |
| • Grade 3 | 17 (19) | 7 (18) | 10 (19) | |
| • NA | 4 | 2 | 2 | |
| Stage (n,%) | 0.054 | |||
| • Stage I | 3 (2) | 0 (0) | 3 (6) | |
| • Stage II | 42 (45) | 14 (35) | 28 (51) | |
| • Stage III | 41 (44) | 20 (50) | 21 (39) | |
| • NA * | 8 (9) | 6 (15) | 2 (4) | |
| Neo/adjuvant CT (n,%) | 0.033 | |||
| • Yes | 64 (68) | 32 (80) | 32 (59) | |
| • No | 30 (32) | 8 (20) | 22 (41) | |
| Relapse (n,%) | 0.001 | |||
| • Not relapsed | 65 (69) | 20 (50) | 45 (83) | |
| • Relapsed | 29 (31) | 20 (50) | 9 (17) |
med [Q1; Q3] (min; max) for numerical variables N (%) for categorical variables. * patients treated with neoadjuvant chemo-radiotherapy